January 7, 2021

Oncology startup launches, two clinical manufacturing sites planned

Waltham biotech Radius Health acquired the rights to Arizona firm Benuvia Therapeutics’ synthetic cannabidiol (CBD) oral drug, which was developed for the treatment of the genetic disorder Prader-Willi syndrome. Radius paid $12.5 million upfront for the drug, with an additional $15 million in milestone payments. The company may also pay up to $45 million for milestones not related to Prader-Willi syndrome, as well as sales-based milestone payments and royalties.

Radius plans to start Phase 2/3 clinical trials in the second half of this year.

In 2016, Radius Health received an MLSC Tax Incentive award with a commitment to create 35 jobs in Massachusetts. The Tax Incentive program provides incentives to companies, of all sizes, looking to expand their efforts by creating new, long-term jobs in Massachusetts.